Biotech IV Monitor

RLAY — Relay Therapeutics Inc.

$3.5B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Relay Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2028.

Next readoutApril 2028in ~17 months
Upcoming readouts31 Phase 3
Market cap$3.5B
Cash & investments$849M~10 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04

Upcoming readouts

Phase 3 Zovegalisib
PIK3CA Mutation; HER2- Negative Breast Cancer · NCT06982521
April 2028
Recruiting
Phase 1/2 RLY-8161
Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors · NCT07584226
May 2029
Recruiting
Phase 2 RLY-2608
PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations · NCT06789913
July 2031
Recruiting

Cash position

Relay Therapeutics Inc. reported $849M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $82M; at that rate the cash would last about 10 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow RLAY, you can start the conversation.
Track RLAY in real time
See live implied volatility for RLAY and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on RLAY
Contact — questions or corrections about RLAY: dukeupt@gmail.com